Traversa Sergio's Form 4 filing
Relmada Therapeutics, Inc. (RLMD) · filed Sep 11, 2026
- Accession no.
- 0001213900-26-098969
- Filed
- Sep 11, 2026, 7:30 AM ET
- Trade date
- Sep 9-10, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $828.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Traversa SergioCIK 0001565832 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Purchase prices range from $4.15 to $4.22 per share, inclusive.
Referenced by the price of 1 transaction in Table I.
- F3
Purchase prices range from $4.03 to $4.11 per share, inclusive
Referenced by the price of 1 transaction in Table I.